Age Related Macular Degeneration Market Outlook to 2012
Age Related Macular Degeneration (AMD) is the most common cause of vision loss in the developed world for those over 50 years of age. We estimate there are over 20 million cases in the US and Europe. Dry AMD accounts for 90% of cases and has no suitable cure.
A number of options exist for the treatment of wet AMD. Novartis achieved first to market success with their Visudyne drug in 1999. However work from Pfizer selling Macugen and Lucentis from Genentech have seen it sales reduced. Drug sales will soon see Lucentis aschieve blockbuster status. These drugs are referred to in the press as miracle drugs - saving sight for millions. But issues over prescribing still remain.
Key pricing issues remain critical to success for these drugs in the European and US markets. The UK's health services have refused to take Lucentis due to its cost. With alternatives available how will Genentech overcome this problem, or will they hold firm. Is there room in the market for another player? With Visudyne receiving an extension on its patent a generic competitor may have been held off, but could the market sustain a generic version?
Dry AMD currently has no effective treatment, so market opportunities are available for a first-to-enter product in this market. With blockbuster status sure to happen for a Wet AMD drug, blockbuster status would be guaranteed for a drug tackling the more prevalent Dry AMD. Who will be likely to succeed?
With charts, graphs, figures, tables and analysis this report delivers the very latest developments and an in depth review of the AMD market. This report is a vital addition to gaining an understanding of this growing sector of the pharmaceutical market.
Five key questions this report answer's are:
1 - What is the market potential for AMD drugs over the next 5 years and beyond?
2 - What latest clinical trials/experimental research has been performed to develop Wet AMD drugs and how successful will they be?
3 - What is the global AMD market value of today and the future worth?
4 - How the AMD market will gain blockbuster status and why?
5 - What are the regulatory issues surrounding AMD drugs and pricing issues inherent with these regulations?
With an increasing aged population and unmet medical needs this market is set to grow rapidly, but by how much? This report will tell you. Brought together in one easy to read, easily digested format, this report will keep you fully informed and up-to-date on the global AMD market
Table of Contents
- 1.1 Introduction to the AMD market
- 1.1.1 Dry AMD
- 1.1.2 Wet AMD
- 1.2 Risk Factors associated with AMD
- 1.3 AMD Prevalence and untapped markets
- 1.4 Current therapies
- 1.4.1 Lucentis launched in 2006 by Genentech
- 1.4.2 Macugen launched by Pfizer
- 1.4.3 Visudyne: the first to market product from Novartis
- 1.5 Drug Revenues and forecast 2006-2012
- 1.6 Current Pipeline (in clinical trials and market)
- 1.7 Future Pipeline - current progress
- 1.8 Ongoing research - additional to pharma treatments
- 2.1 Introduction to Age Related Macular Degeneration (AMD)
- 2.2 Dry AMD
- 2.3 Wet AMD
- 2.4 Risk factors associated with AMD
- 3.1 Prevalence of AMD - A profitable market space
- 3.1.1 Prevalence of Wet AMD
- 3.1.2 Prevalence of Dry AMD
- 4.1 Current therapies
- 4.1.1 Lucentis - Genentech's costly potential blockbuster
- 4.1.1.1 Lucentis - How it works and is administered
- 4.1.1.2 Clinical trials - improvements
- 4.1.1.3 Marketing Lucentis - Novartis licensing
- 4.1.1.4 Future prospects
- 4.1.2 Macugen
- 4.1.2.1 Macugen - How it works and is administered
- 4.1.2.2 Clinical trials - Eyetech and Pfizer partner
- 4.1.2.3 Marketing Macugen - OSi buy Eyetech and suffers loss
- 4.1.3 Visudyne - Swiss launch in 1999
- 4.1.3.1 Visudyne - How it works and is administered
- 4.1.3.2 Clinical trials - shows potential in other indications
- 4.1.3.3 Marketing Visudyne - 65 countries now targeted
- 4.1.3.4 Future prospects high with strong sales
- 4.1.4 Retaane
- 4.1.4.1 Retanne - how it works and is administered
- 4.1.4.2 Clinical trials fail but strategy planned again
- 4.1.4.3 Future marketing of Retaane if approvable
- 4.1.4.4 Competitive market - cost and dose become issues
- 4.1.5 Others on the market
- 4.1.5.1 Avastin - the off label cancer therapy
- 4.1.5.1.1 Avastin - How it works and is administered
- 4.1.5.1.2 Marketing Avastin - the most successful oncology launch
- 4.1.5.1.3 Lucentis v Avastin - cost and dose but no clinical trial
- 4.1.5.2 Retisert
- 4.1.5.2.1 Retisert - How it works and is administered
- 4.1.5.2.2 Clinical trials - patent expires in 2010
- 4.1.5.2.3 Marketing Retisert - sales set to decrease
- 4.1.5.1 Avastin - the off label cancer therapy
- 4.1.1 Lucentis - Genentech's costly potential blockbuster
- 5.1 Macugen - increasing now but will it last?
- 5.2 Visudyne - sales already declining
- 5.3 Lucentis - the industry blockbuster?
- 6.1 Pipeline analysis
- 6.1.1 Retaane - resubmitted for trials
- 6.1.2 Avastin - results to be seen by 2009
- 6.1.3 Retisert - will it impact other drugs?
- 6.1.4 Laserphyrin - to focus on PDT?
- 6.1.5 Adcortyl-A - 40% see sign of improvement
- 6.1.6 Photrex - phase III complete
- 6.2 Future pipeline
- 6.3 Non Pharma treatments
- 6.3.1 Cortical Implants
- 6.3.2 Retinal Chips - ‘artificial' retina allows blind to see
- 6.3.3 Retinal transplantation - phase II now in place
- 6.3.4 Implantable Miniature Telescope (IMT)
- 6.3.5 Microcurrent Stimulation - therapy for early stage AMD
- 6.3.6 Rheopheresis - still unproven for dry AMD
- 6.3.7 Photodynamic Therapy - the non-thermal laser
- 6.3.8 Radiation
- 6.3.9 Conventional or Photon Beam Radiation
- 6.3.10 Complement Factor H (CFH) gene
- 7.1 Genentech - alliances key to success
- 7.2 Pfizer - largest R&D, but not ophthalmology specific
- 7.3 Novartis - ranked the strongest pipeline in industry
- 7.4 Companies Overview
- 3.1 The prevalence of three major causes of blindness among adults 40 years and older in the US.
- 3.2 The regional market share of AMD.
- 3.3 Regional prevalence of AMD in 2006 and 2025
- 4.1 Visudyne's revenue sales in 2004 and 2005
- 5.1 Macugen revenue forecast ($m), 2007-2012
- 5.2 Visudyne revenue forecast ($m), 2007-2011
- 5.3 Lucentis revenue forecast ($m), 2007-2012
- 7.1 Genentech's total product sales ($m), 2002-2006
- 7.2 Genentech's R&D expenditure ($m), 2002-2006
- 7.3 Pfizer's total sales ($m), 2001-2005
- 7.4 Pfizer's R&D expenditure ($m), 2001-2005
- 7.5 Novartis total sales ($m), 2001-2005
- 7.6 Novartis R&D expenditure ($m), 2001-2005
- 8.1 Regional AMD market (millions) 2006
- 1.1 Regional prevalence of AMD 2006
- 1.2 Revenue forecasts for the three main drugs for AMD, 2007-2012
- 1.3 The amount of drugs in the AMD pipeline and their current progress
- 3.1: A summary of the worldwide prevalence of AMD
- 3.2: The prevalence of wet AMD worldwide in 2006 and 2025
- 3.3: The prevalence of dry AMD worldwide in 2006 and 2025
- 4.1 Visudyne's predicted revenues ($m) by Morgan Stanley and Visiongain in 2006, 2009, 2012
- 4.2 The advantages and disadvantages of Lucentis and Avastin
- 5.1 Macugen revenue and growth forecast ($m), 2007-2012
- 5.2 Visudyne revenue and growth forecast ($m), 2007-2011
- 5.3 Lucentis revenue and growth forecast ($m), 2007-2012
- 6.1: Pipeline AMD products, 2007
Other users found this report page using the following search terms: AMD blindness ocular retinopathy macular degeneration market amd prevalence lucentis wet dry age related
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.